Edition:
India

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

564.40INR
25 Jul 2017
Change (% chg)

Rs-5.35 (-0.94%)
Prev Close
Rs569.75
Open
Rs571.00
Day's High
Rs571.40
Day's Low
Rs562.40
Volume
510,032
Avg. Vol
1,208,766
52-wk High
Rs621.25
52-wk Low
Rs480.20

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.49
Market Cap(Mil.): Rs458,462.59
Shares Outstanding(Mil.): 804.67
Dividend: 2.00
Yield (%): 0.35

Financials

  CIPL.NS Industry Sector
P/E (TTM): 45.61 13.33 16.92
EPS (TTM): 12.49 -- --
ROI: 6.90 -7.43 -5.76
ROE: 8.37 -6.99 -5.08

BRIEF-India's Cipla launches rectal artesunate suppositories for severe malaria in young children

* Launches quality-assured rectal artesunate suppositories for severe malaria in young children

25 Jul 2017

MEDIA-India's Cipla, Novartis explore marketing tie-up - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

14 Jul 2017

BRIEF-Dr.Reddy's Labs recalls Cipla-made zenatane capsule from U.S. markets

* Dr.Reddy's Laboratories clarifies on news item, "Dr Reddy's recalls 3.25l cartons Cipla-made acne drug from US".

15 Jun 2017

BUZZ-India's Cipla plunges to 11-mth low on unexpected Q4 loss

** Cipla Ltd drops as much as 4.7 pct to 480.2 rupees, its lowest since June 27, 2016

26 May 2017

Cipla lowers bio drugs investment, sharpens focus on respiratory

MUMBAI Cipla Ltd , India's fifth-largest drugmaker by sales, plans to reduce investment in biosimilars to sharpen its focus on building a portfolio of high-margin respiratory products, the company's chief executive said on Thursday.

26 May 2017

UPDATE 1-India's Cipla lowers bio drugs investment, sharpens focus on respiratory

* Posts Q4 loss vs. analysts' forecast for profit (Recasts with CEO's comments)

26 May 2017

Indian drugmaker Cipla narrows loss in Jan-March, misses forecasts

MUMBAI, May 25 Cipla Ltd, India's fifth-largest drugmaker by sales, reported a smaller quarterly loss for January-March, but missed expectations of a profit for the period.

25 May 2017

BRIEF-India's Cipla March-qtr loss narrows

* Consol march quarter total income from operations 35.82 billion rupees

25 May 2017

BUZZ-India's Cipla hits 3-1/2-month low, technicals signal further downside

** Drug maker Cipla Ltd falls as much as 1.98 pct to 562.7 rupees, to its lowest since Jan 3

21 Apr 2017

BRIEF-Cipla U.S. arm signs worldwide licensing deal with MEDRx

* Medrx is eligible to receive up to USD 30 million cumulatively through upfront and developmental, regulatory, and commercial milestones payments

06 Apr 2017

Earnings vs. Estimates